Development of novel vaccine candidates and challenge models for Plasmodium vivax

Development of novel vaccine candidates and challenge models for Plasmodium vivax

Plasmodium vivax is the most widely distributed human malaria parasite in the world and despite nearly 2.5 billion people living at risk, only four vaccines have been assessed in phase I clinical trials and only one has progressed to a phase II trial showing no sterile efficacy. We started to develo...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Alves, E, Salman, A, Janse, C, Khan, S, Hill, A, Reyes-Sandoval, A
Formáid:	Journal article
Foilsithe / Cruthaithe:	BioMed Central 2014

Míreanna comhchosúla

Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine
de réir: Alves, E, et al.
Foilsithe / Cruthaithe: (2017)

Plasmodium vivax malaria vaccines: why are we where we are?
de réir: Reyes-Sandoval, A, et al.
Foilsithe / Cruthaithe: (2013)

Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models
de réir: Salman, A, et al.
Foilsithe / Cruthaithe: (2017)

The challenges of Plasmodium vivax human malaria infection models for vaccine development
de réir: Roobsoong, W, et al.
Foilsithe / Cruthaithe: (2023)

Tailoring a P. vivax vaccine to enhance efficacy through a combination of a CSP Virus-Like Particle Rv21 and TRAP viral vectors
de réir: Atcheson, E, et al.
Foilsithe / Cruthaithe: (2018)

Assessment of the Plasmodium falciparum pre-erythrocytic antigen UIS3 as a potential candidate for a malaria vaccine
de réir: Longley, R, et al.
Foilsithe / Cruthaithe: (2016)

Protective efficacy of peptides from Plasmodium vivax circumsporozoite protein
de réir: Atcheson, E, et al.
Foilsithe / Cruthaithe: (2020)

Chimeric Plasmodium falciparum parasites expressing Plasmodium vivax circumsporozoite protein fail to produce salivary gland sporozoites
de réir: Marin-Mogollon, C, et al.
Foilsithe / Cruthaithe: (2018)

Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites.
de réir: Bauza, K, et al.
Foilsithe / Cruthaithe: (2014)

Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates.
de réir: Longley, R, et al.
Foilsithe / Cruthaithe: (2015)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
de réir: Minassian, A, et al.
Foilsithe / Cruthaithe: (2011)

A library of Plasmodium vivax recombinant merozoite proteins reveals new vaccine candidates and protein-protein interactions
de réir: Hostetler, JB, et al.
Foilsithe / Cruthaithe: (2015)

The Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites as a candidate for preerythrocytic and transmission-blocking vaccines.
de réir: Espinosa, D, et al.
Foilsithe / Cruthaithe: (2016)

Challenges in the Control and Elimination of Plasmodium vivax Malaria
de réir: Asih, P, et al.
Foilsithe / Cruthaithe: (2018)

Towards an effective vaccine against Plasmodium vivax malaria
de réir: Rawlinson, T
Foilsithe / Cruthaithe: (2018)

Homologous and heterologous prime boost vaccinations with distinct variants of Plasmodium vivax circumsporozoite protein (CSP) protects mice against transgenic PB/PV sporozoite challenge
de réir: Freitas, E, et al.
Foilsithe / Cruthaithe: (2017)

The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.
de réir: Ramjanee, S, et al.
Foilsithe / Cruthaithe: (2007)

An in vitro T cell killing assay to assess new Plasmodium falciparum vaccine candidates
de réir: Longley, R, et al.
Foilsithe / Cruthaithe: (2013)

Acquisition and longevity of antibodies to Plasmodium vivax pre-erythrocytic antigens in western Thailand.
de réir: Longley, R, et al.
Foilsithe / Cruthaithe: (2016)

Acquisition and longevity of antibodies to Plasmodium vivax pre-erythrocytic antigens in western Thailand
de réir: Longley, R, et al.
Foilsithe / Cruthaithe: (2016)

Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge
de réir: de Camargo, T, et al.
Foilsithe / Cruthaithe: (2018)

Attacking Plasmodium vivax
de réir: Baird, J
Foilsithe / Cruthaithe: (2016)

Epidemiology of Plasmodium vivax in Indonesia
de réir: Baird, J, et al.
Foilsithe / Cruthaithe: (2016)

Taking on Plasmodium vivax malaria: a timely and important challenge
de réir: von Seidlein, L, et al.
Foilsithe / Cruthaithe: (2021)

Plasmodium vivax susceptibility to ferroquine.
de réir: Leimanis, M, et al.
Foilsithe / Cruthaithe: (2010)

Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development
de réir: Mertens, JE, et al.
Foilsithe / Cruthaithe: (2024)

Plasmodium vivax transmission in Africa
de réir: Howes, R, et al.
Foilsithe / Cruthaithe: (2015)

Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies
de réir: Payne, R, et al.
Foilsithe / Cruthaithe: (2017)

Modelling the incidence of Plasmodium vivax and Plasmodium falciparum malaria in Afghanistan 2006-2009
de réir: Alegana, V, et al.
Foilsithe / Cruthaithe: (2014)

Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle.
de réir: Villarreal-Ramos, B, et al.
Foilsithe / Cruthaithe: (2014)

Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle
de réir: Villarreal-Ramos, B, et al.
Foilsithe / Cruthaithe: (2014)

Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle
de réir: Villarreal-Ramos, B, et al.
Foilsithe / Cruthaithe: (2017)

51 years in of Chikungunya clinical vaccine development: a historical perspective
de réir: Reyes-Sandoval, A
Foilsithe / Cruthaithe: (2019)

Current trends in Zika vaccine development.
de réir: Lagunas-Rangel, FA, et al.
Foilsithe / Cruthaithe: (2017)

Biological, immunological and functional properties of two novel multi-variant chimeric recombinant proteins of CSP antigens for vaccine development against Plasmodium vivax infection
de réir: Shabani, S, et al.
Foilsithe / Cruthaithe: (2017)

The genetic diversity of Plasmodium vivax populations.
de réir: Cui, L, et al.
Foilsithe / Cruthaithe: (2003)

Global epidemiology of Plasmodium vivax
de réir: Howes, R, et al.
Foilsithe / Cruthaithe: (2016)

Global Epidemiology of Plasmodium vivax
de réir: Howes, R, et al.
Foilsithe / Cruthaithe: (2016)

The epidemiology of Plasmodium vivax. Preface.
de réir: Hay, S, et al.
Foilsithe / Cruthaithe: (2013)

Rosette formation by Plasmodium vivax.
de réir: Udomsanpetch, R, et al.
Foilsithe / Cruthaithe: (1995)